Day: September 23, 2023

Ascendis Pharma Presents Results from Long-Term enliGHten Trial of TransCon™ hGH in Pediatric Growth Hormone Deficiency

Written by Customer Service on . Posted in Public Companies.

– The majority of children and adolescents treated once weekly with TransCon hGH (lonapegsomatropin) met or exceeded average parental height SDS at time of treatment completion or last visit – Trial demonstrated the long-term safety of TransCon hGH in patients treated up to 6 years COPENHAGEN, Denmark, Sept. 23, 2023 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND) today announced results from enliGHten, the Company’s open-label extension trial evaluating the long-term safety and efficacy of TransCon hGH as a once-weekly treatment for children and adolescents with growth hormone deficiency (GHD). Results were shared today in Poster LB-17 at ESPE 2023, the annual meeting of the European Society for Paediatric Endocrinology being held in The Hague, September 21-23. The enliGHten trial enrolled 298 participants (mean...

Continue reading

Reflex Advanced Materials Corp. Amends Non-Brokered Private Placement

Written by Customer Service on . Posted in Public Companies.

// NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES // VANCOUVER, British Columbia, Sept. 22, 2023 (GLOBE NEWSWIRE) — Reflex Advanced Materials Corp. (CSE:RFLX) (FSE:HF2) (“Reflex” or the “Company”) announces an amendment to the terms of its non-brokered private placement financing (the “Private Placement”) previously announced on August 21, 2023. The Private Placement is now comprised of up to 5,000,000 units of the Company (“Units”) at an updated price of $0.20 per Unit for aggregate gross proceeds of up to $1,000,000. Each Unit continues to consist of one (1) common share in the capital of the Company (“Share”) and one-half (1/2) of one (1) Share purchase warrant (“Warrant”), whereby each whole Warrant will entitle the holder thereof to purchase an additional Share at an exercise...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.